Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial
Supplement Provides Hope for Large Group with Serial Spike Protein Exposures
By Peter A. McCullough
Approximately two thirds of the world’s population have taken a COVID-19 vaccine, and now most regret it. In countries like Australia, the population was vaccinated first and then most became COVID-19 vaccine failures by contracting the SARS-CoV-2 infection. In the US, many contracted the virus first in 2020 and 2021 and later
were effectively forced into an unnecessary shot with COVID-19 vaccine mandates. So many of my patients have been asking what can they do on their own to mitigate some of the adverse effects of both SARS-CoV-2 infection and the vaccine. Fessler and coworkers have recently completed a trial in patients who had the infection first and then took an ill-advised vaccine.
This study was conducted between June 2021 and May 2022. Healthy adults between the ages of 18 and 65 years, were eligible if they previously experienced asymptomatic, mild, or moderate COVID-19 infection and subsequently received the full primary series of a COVID-19 vaccine at least 3 months prior to enrollment. Participants assigned to the active curcumin 500 mg HydroCurc® twice a day for the four-week trial period versus matching placebo. Each 500 mg dose of HydroCurc contains over 90% curcuminoids complexed with LipiSperse. LipiSperse is a novel delivery system shown to enhance the bioavailability of hydrophobic molecules.
The results of the linear regression analyses revealed that assignment to the CURC group was associated with significantly lower mean post-trial concentrations of the inflammatory biomarkers, IL-6 and MCP-1, after controlling for dietary factors. I was amazed that a supplement was able to move any of the inflammatory markers given the difficulties we have faced with SARS-CoV-2 Spike protein associated inflammation.
This study has all the caveats of small randomized trials, however, given the background strength of data on curcumin and particularly the nano/liposomal formulations on cardiovascular risk factors, I believe it offers considerable hope to patients who have had both COVID-19 and one or more injections of the vaccines. It may be an ideal supplement for older individuals with metabolic syndrome and heart disease who have fallen into the COVID-19 trap. Clearly more research is warranted.
If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.
Fessler SN, Chang Y, Liu L, Johnston CS. Curcumin Confers Anti-Inflammatory Effects in Adults Who Recovered from COVID-19 and Were Subsequently Vaccinated: A Randomized Controlled Trial. Nutrients. 2023 Mar 23;15(7):1548. doi: 10.3390/nu15071548. PMID: 37049389; PMCID: PMC10096702.
Lavian S, Mardaneh P, Bagherniya M, Emami SA, Butler AE, Sahebkar A. The effect of synthetic curcumin analogues on obesity, diabetes and cardiovascular Disease: a literature review. Curr Med Chem. 2023 Mar 2. doi: 10.2174/0929867330666230302114522. Epub ahead of print. PMID: 36861802.